Pages that link to "Q35793182"

The following pages link to Characterizing the tumor response to treatment with combretastatin A4 phosphate (Q35793182):

Displaying 21 items.

• Antivascular ultrasound therapy extends survival of mice with implanted melanomas (Q30475723) (← links)
• Segmentation of dynamic contrast enhanced magnetic resonance imaging data (Q31165580) (← links)
• A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer (Q33389126) (← links)
• An efficient synthetic strategy for obtaining 4-methoxy carbon isotope labeled combretastatin A-4 phosphate and other Z-combretastatins (Q33823154) (← links)
• In vivo functional differences in microvascular response of 4T1 and Caki-1 tumors after treatment with OXi4503 (Q34296779) (← links)
• Spatial morphological and molecular differences within solid tumors may contribute to the failure of vascular disruptive agent treatments. (Q34478450) (← links)
• Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503 (Q34491366) (← links)
• Multiparametric MRI biomarkers for measuring vascular disrupting effect on cancer (Q34538659) (← links)
• Evaluation of tumor ischemia in response to an indole-based vascular disrupting agent using BLI and (19)F MRI. (Q35402062) (← links)
• Metastasis: recent discoveries and novel treatment strategies (Q36407511) (← links)
• Small Molecule Sequential Dual-Targeting Theragnostic Strategy (SMSDTTS): from Preclinical Experiments towards Possible Clinical Anticancer Applications (Q36609881) (← links)
• Diverse responses to vascular disrupting agent combretastatin a4 phosphate: a comparative study in rats with hepatic and subcutaneous tumor allografts using MRI biomarkers, microangiography, and histopathology (Q36613314) (← links)
• Current status of antivascular therapy and targeted treatment in the clinic (Q37063510) (← links)
• Novel targets with potential therapeutic applications in osteosarcoma (Q37263375) (← links)
• Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). (Q37458557) (← links)
• Microtubule destabilising agents: far more than just antimitotic anticancer drugs (Q38952778) (← links)
• Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management (Q47566245) (← links)
• The vascular disrupting agent combretastatin A-4 phosphate causes prolonged elevation of proteins involved in heme flux and function in resistant tumor cells (Q49302678) (← links)
• Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and Anti-Angiogenic Agents to Treat Cancer (Q51795514) (← links)
• Spatial Characterization of Tumor Perfusion Properties from 3D DCE-US Perfusion Maps are Early Predictors of Cancer Treatment Response (Q93216659) (← links)
• The influence of hypoxia and energy depletion on the response of endothelial cells to the vascular disrupting agent combretastatin A-4-phosphate (Q96576569) (← links)